ScreenCell® Will Standardize Its CTC Isolation Kit Range in 2026

Starting January 1st, 2026, ScreenCell® kits will be standardized around a single format: 2 filtration units and 1 dilution buffer per kit, all in completely redesigned packaging. A 360° evolution designed for optimization and simplicity.
Device CYTO et MB - 2 dispositifs ScreenCell de détection des cellules tumorales circulantes

The New Format of ScreenCell® Kits

screencell kits kits screencell
The future composition of ScreenCell kits

ScreenCell® is pleased to announce that starting next January 1st, its entire range of circulating tumor cell (CTC) isolation kits will transition to a standardized format: 2 filtration units per kit with 1 dilution buffer.

This shift to 2 filtration units per kit stems from a reality observed in the field. By standardizing our range, we respond to both actual laboratory practices and our commitment to establishing the principle of “1 ScreenCell® kit = 1 patient”. By harmonizing our range around this logic, we simplify and optimize all processes.

Which Kits Are Affected?

From left to right, the CSB, CYTO, MB, and MBSB kits

This change will affect all ScreenCell® kits containing more than 2 filtration units, namely the CYTO, CSB, MB, and MBSB kits.

First, the CYTO and CSB kits, each containing 4 filtration units, will transition to 2 filtration units. Their filtration capacity will thus evolve from 12 ml of whole blood (4 units × 3 ml) to 6 ml (2 units × 3 ml).

Next, the MB and MBSB kits will also evolve by transitioning from 3 to 2 filtration units. Additionally, each MB filtration unit will now process between 3 and 6 ml of whole blood, depending on the application.
Indeed, we recommend 3 ml for molecular analyses and 6 ml for cell culture. Thus, these kits will process between 6 and 12 ml of whole blood, compared to 18 ml with the current configuration.

Finally, our other kits LCD, FCD, and FCD-SP, already have 2 filtration units each, so they are not affected by this change.

Less Blood, but Equivalent Performance

ScreenCell MB kit Video

Despite the decrease in the number of filtration units, the recovery rate of circulating tumor cells (CTCs) will remain identical. This new configuration will even enable better molecular biology results with MB and MBSB kits when using 3 ml of blood.

Indeed, through internal studies, we observed that reducing the volume of blood processed limits contamination from white blood cells, thus optimizing sample purity and the quality of downstream molecular analyses, particularly for mutation identification.

New Packaging,
Even Simpler and More Eco-Friendly

Since good news never comes alone, this change will be accompanied by completely redesigned packaging. Indeed, our new packaging has been designed to optimize storage space in work environments while facilitating rapid kit identification.

Furthermore, ScreenCell® remains true to its environmental values by maintaining fully recyclable cardboard for all packaging. A commitment we reinforce by working with local suppliers.

An Anticipated and Supported Transition

We are aware that this change may cause some disruption to ongoing projects. This is why we are providing a dedicated contact form to support anyone with questions who wishes to discuss with our experts.

We are available to answer your questions and to support you through this transition.

Have a Question? Contact Us

Contact

Quentin DUBIEL

Communications and Webmarketing Officer
qdubiel@screencell.com

Share the article

Our latest news

Liquid biopsy for enhancing patient care through reliable CTC analysis

Want to learn more?

Download our brochure

Follow ScreenCell® on LinkedIn